Taiwan-based Brain Navi Biotechnology partners with First Securities Inc. for IPO counseling, aiming to accelerate global expansion of its AI-powered surgical robots—led by flagship neurosurgical system NaoTrac—as it positions itself at the forefront of next-gen smart medical technology.